Antisoma cancer drug trials show positive results

SarahTurner

LONDON (MarketWatch) -- Biopharmaceutical company Antisoma
uk:asm
said Monday that a phase II trial of AS1404 for ovarian cancer showed that AS1404 had a tumour response rate of 61.3%, compared with 54.8% for those receiving chemotherapy alone. To date, AS1404 has been well tolerated and has not exacerbated the side effects of chemotherapy, the company said. Antisoma also said that a phase II lung cancer trial of AS1404 showed positive data, with patients showing increased tumour response rates, longer time to disease progression and enhanced survival compared with patients receiving standard chemotherapy alone. Separately, Antisoma said that in a phase I trial of R1550, a safety study of patients with metastatic breast cancer showed that the drug was well tolerated at the maximum dose tested. Antisoma has reached agreement with Roche to regain all rights to R1550.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.